Sign in
PVLA Stock Price, Chart, Stats & News
Palvella Therapeutics, Inc.
Save
Palvella Therapeutics, Inc. (PVLA) does not currently pay a dividend.
2.10B
Market cap
–
Current P/E
–
Forward P/E
PVLA chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -49.23% |
ROE | -64.41% |
D/E | 0.41x |
Interest coverage ratio | -5.88x |
PVLA valuation
P/E | – |
P/S | – |
P/B | 32.14x |
P/CF | -48.81x |
P/FCF | -52.22x |
P/OCF | -48.81x |
PEG | -2.48x |
EV multiple | -72.09x |
About
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations.
Similar securities
Based on sector and market capitalization
Report issue